Jonathan Barratt

23.5k total citations · 7 hit papers
291 papers, 6.6k citations indexed

About

Jonathan Barratt is a scholar working on Nephrology, Hematology and Immunology. According to data from OpenAlex, Jonathan Barratt has authored 291 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 224 papers in Nephrology, 94 papers in Hematology and 82 papers in Immunology. Recurrent topics in Jonathan Barratt's work include Renal Diseases and Glomerulopathies (209 papers), Platelet Disorders and Treatments (70 papers) and Chronic Kidney Disease and Diabetes (43 papers). Jonathan Barratt is often cited by papers focused on Renal Diseases and Glomerulopathies (209 papers), Platelet Disorders and Treatments (70 papers) and Chronic Kidney Disease and Diabetes (43 papers). Jonathan Barratt collaborates with scholars based in United Kingdom, United States and Germany. Jonathan Barratt's co-authors include John Feehally, Chee Kay Cheung, Karen Molyneux, Anthony C Smith, Jürgen Floege, See Cheng Yeo, Katharine Buck, Peter Topham, Alice C. Allen and Haresh Selvaskandan and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Jonathan Barratt

262 papers receiving 6.4k citations

Hit Papers

Long-Term Outcomes in IgA Nephropathy 2023 2026 2024 2025 2023 2023 2023 2023 2024 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-Term Outcomes in IgA Nephropathy
    2023 169 citations David Pitcher, Fiona Braddon et al. Clinical Journal of the American Society of Nephrology profile →
  2. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
    2023 121 citations Richard Lafayette, Jens Kristensen et al. profile →
  3. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
    2023 100 citations Jonathan Barratt, Laura Kooienga et al. profile →
  4. IgA nephropathy
    2023 81 citations Peter Boor, Vladimı́r Tesař et al. profile →
  5. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy
    2024 51 citations Richard Lafayette, Jürgen Floege et al. Kidney International profile →
  6. The pathogenesis of IgA nephropathy and implications for treatment
    2024 43 citations Chee Kay Cheung, Suceena Alexander et al. Nature Reviews Nephrology profile →
  7. The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies
    2024 39 citations Chee Kay Cheung, Jonathan Barratt et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan Barratt United Kingdom 45 4.8k 1.7k 1.6k 1.5k 944 291 6.6k
Arrigo Schieppati Italy 34 1.9k 0.4× 358 0.2× 356 0.2× 296 0.2× 537 0.6× 75 4.2k
Hong Xiao United States 43 1.1k 0.2× 212 0.1× 2.7k 1.7× 348 0.2× 2.0k 2.2× 157 8.3k
Alexander Strasak Austria 39 574 0.1× 270 0.2× 363 0.2× 414 0.3× 591 0.6× 83 4.4k
Jim C. Oates United States 35 399 0.1× 197 0.1× 1.6k 1.0× 447 0.3× 893 0.9× 113 4.2k
Arthur Kavanaugh United States 44 283 0.1× 3.5k 2.0× 4.1k 2.6× 1.2k 0.8× 1.4k 1.5× 195 11.4k
John W. Adamson United States 37 1.0k 0.2× 5.5k 3.2× 934 0.6× 97 0.1× 1.3k 1.3× 116 8.0k
Tony Reiman Canada 47 195 0.0× 1.5k 0.9× 449 0.3× 659 0.5× 2.3k 2.4× 181 13.3k
Scott M. Wasserman United States 54 362 0.1× 635 0.4× 1.9k 1.2× 250 0.2× 1.6k 1.7× 129 14.4k
Joan C. Egrie United States 29 1.9k 0.4× 5.5k 3.2× 849 0.5× 71 0.0× 1.4k 1.5× 49 7.7k
Maria Gavriatopoulou Greece 37 187 0.0× 2.5k 1.4× 465 0.3× 522 0.4× 2.2k 2.4× 376 5.5k

Countries citing papers authored by Jonathan Barratt

Since Specialization
Citations

This map shows the geographic impact of Jonathan Barratt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Barratt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Barratt more than expected).

Fields of papers citing papers by Jonathan Barratt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Barratt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Barratt. The network helps show where Jonathan Barratt may publish in the future.

Co-authorship network of co-authors of Jonathan Barratt

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Barratt. A scholar is included among the top collaborators of Jonathan Barratt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Barratt. Jonathan Barratt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Jingyi, Yuemiao Zhang, Zhao Zhang, et al.. (2025). B Cell-Specific Deletion of C1GALT1 Elevates Serum Gd-IgA1 but Fails to Induce Mesangial IgA Deposition in Humanized IGHA1 Mice. Journal of the American Society of Nephrology. 36(10S).
2.
Cheung, Chee Kay, Suceena Alexander, Heather N. Reich, et al.. (2024). The pathogenesis of IgA nephropathy and implications for treatment. Nature Reviews Nephrology. 21(1). 9–23. 43 indexed citations breakdown →
3.
Heerspink, Hiddo J.L., Alan G. Jardine, Donald E. Kohan, et al.. (2024). Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy. Kidney International Reports. 10(1). 217–226. 6 indexed citations
4.
Tumlin, James A., Sreedhar Mandayam, Frank B. Cortazar, et al.. (2024). WCN24-762 UPDATED RESULTS FROM THE RUBY-3 STUDY OF POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGONIST, IN AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS. Kidney International Reports. 9(4). S505–S505. 1 indexed citations
5.
Trachtman, Howard, Jai Radhakrishnan, Michelle N. Rheault, et al.. (2024). Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study. Kidney International Reports. 9(4). 1020–1030. 2 indexed citations
6.
Oni, Louise, et al.. (2024). IgA Nephropathy: Emerging Mechanisms of Disease. Indian Journal of Nephrology. 34(4). 297–309. 3 indexed citations
7.
Hölscher, David L., Nassim Bouteldja, María Luisa Russo, et al.. (2023). Next-Generation Morphometry for pathomics-data mining in histopathology. Nature Communications. 14(1). 470–470. 67 indexed citations
8.
Zhang, Hong, Dana V. Rizk, Vlado Perkovic, et al.. (2023). Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney International. 105(1). 189–199. 62 indexed citations
9.
Rizk, Dana V., Brad H. Rovin, Hong Zhang, et al.. (2023). Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study. Kidney International Reports. 8(5). 968–979. 35 indexed citations
10.
Pitcher, David, Fiona Braddon, Bruce M. Hendry, et al.. (2023). Long-Term Outcomes in IgA Nephropathy. Clinical Journal of the American Society of Nephrology. 18(6). 727–738. 169 indexed citations breakdown →
11.
Selvaskandan, Haresh, Charlotte Boys, Izabella Pawluczyk, & Jonathan Barratt. (2023). #3979 DIGITAL SPATIAL PROFILING CAN BE USED TO STUDY GLOMERULAR ENDOTHELIAL CELLS IN IGA NEPHROPATHY. Nephrology Dialysis Transplantation. 38(Supplement_1). 1 indexed citations
12.
Barratt, Jonathan, et al.. (2023). Efficacy and Safety of Ravulizumab in a Phase 2 Randomized Controlled Trial in IgA Nephropathy. Journal of the American Society of Nephrology. 34(11S). B8–B8. 2 indexed citations
13.
Ehrchen, Jan, Karen Molyneux, Jonathan Barratt, et al.. (2022). Systemic Activation of Neutrophils by Immune Complexes Is Critical to IgA Vasculitis. The Journal of Immunology. 209(6). 1048–1058. 12 indexed citations
14.
Barratt, Jonathan, Laura Kooienga, Irfan Agha, et al.. (2022). Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients With IgA Nephropathy. Journal of the American Society of Nephrology. 33(11S). 503–503. 2 indexed citations
15.
Alexander, Suceena, Santosh Varughese, Grace Rebekah, et al.. (2021). Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort. Kidney International Reports. 7(2). 305–318. 10 indexed citations
16.
Barratt, Jonathan, Jens Kristensen, & Andrew Stone. (2020). The NefIgArd trial: The Effect of Nefecon® (Budesonide) in Patients with Primary IgA Nephropathy at Risk of Developing ESRD. Journal of the American Society of Nephrology. 31(10S). 571–572. 1 indexed citations
17.
Molyneux, Karen, et al.. (2020). Nefecon® (Budesonide) Selectively Reduces Circulating Levels of BAFF (BLyS) and Soluble BCMA and TACI in IgA Nephropathy. Journal of the American Society of Nephrology. 31(10S). 26–26. 1 indexed citations
18.
Barratt, Jonathan, et al.. (2020). Roxadustat for the Treatment of Anemia in CKD Patients Not on Dialysis (NDD): A Phase 3, Randomized, Open-Label, Active-Controlled Study. Journal of the American Society of Nephrology. 31(10S). 1–1. 2 indexed citations
19.
Thompson, Aliza, Kevin Carroll, Lesley A. Inker, et al.. (2019). Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clinical Journal of the American Society of Nephrology. 14(3). 469–481. 161 indexed citations
20.
Haas, Mark, Jacobien C. Verhave, Zhihong Liu, et al.. (2016). A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy. Journal of the American Society of Nephrology. 28(2). 691–701. 216 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arrigo Schieppati Breakdown of academic impact, for papers by Hong Xiao Breakdown of academic impact, for papers by Alexander Strasak Breakdown of academic impact, for papers by Jim C. Oates Breakdown of academic impact, for papers by Arthur Kavanaugh Breakdown of academic impact, for papers by John W. Adamson Breakdown of academic impact, for papers by Tony Reiman Breakdown of academic impact, for papers by Scott M. Wasserman Breakdown of academic impact, for papers by Joan C. Egrie Breakdown of academic impact, for papers by Maria Gavriatopoulou
Rankless by CCL
2026